Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ONO PHARMACEUTICAL CO., LTD. : Voluntary adoption of International Financial Reporting Standards (IFRS)(64.9KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/13/2013 | 01:15pm CEST

May 13, 2013
ONO PHARMACEUTICAL CO., LTD. Corporate Communications
TEL: +81-6-6263-5670

Voluntary adoption of International Financial Reporting Standards (IFRS)

Ono Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, President: Gyo Sagara) resolved at the meeting of Board of Directors held today that IFRS is to be adopted to its group's consolidated financial reports and consolidated calculation documents ending on March 31st, 2014. Its financial reports and documents used to be based on Japan Generally Accepted Accounting Principles (Japan GAAP).
Our group has been facilitating business development such as research and development and licensing activities globally in the U.S.A, Europe and Asian regions as well as in Japan. Additionally foreign investors account for about 30 % of the total shareholders as of March 31st,
2013, which has shown large proportion of foreign investors from the past. With these situations considered, we have decided to voluntarily adopt IFRS to disclose financial information based on international standards, improve comparability and enhance convenience of stakeholders
including shareholders, investors and business partners.
Ref: <Schedule of disclosure of financial information in association with the change of accounting standards>

May 2013

Flash Report and consolidated calculation document ending on

March 31st, 2013

Japan GAAP

June 2013

Annual Report ending on March 31st, 2013

Japan GAAP

Financial information on 1Q to 3Q ending on March 31st, 2014

Japan GAAP

May 2014

Flash Report and consolidated calculation document ending on

March 31st, 2014

IFRS

June 2014

Annual Report ending on March 31st, 2014

IFRS

Consolidated Financial Forecast in Fiscal Year ended March 31, 2014 (FY2013) under IFRS

Table below shows trial IFRS calculation of the consolidated forecast for the fiscal year ending March 31, 2014, disclosed today.

(Billion JPY)

IFRS (1)

J-GAAP (2)

Difference ((1) - (2))

Net sales

146.3

148.3

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
09:10a ONO PHARMACEUTICAL : Submits Supplemental Application of OPDIVO« (Nivolumab) for..
07/14 ONO PHARMACEUTICAL : Notice Concerning Determination of Details of Issuance of S..
07/11 CELYAD : and ONO strike deal for NKR-2 in Japan, Korea and Taiwan
07/11 CELYAD : SA Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunot..
07/11 ONO PHARMACEUTICAL : enters into license agreement with Celyad for its allogenei..
07/06 ONO PHARMACEUTICAL : European Commission approves ONGENTYS« (opicapone) a novel ..
07/04 ONO RECEIVES MANUFACTURING AND MARKE : Carfilzomib; development code: ONO-7057),..
06/29 ONO PHARMACEUTICAL : Notice Concerning Issuance of Stock Options (Stock Acquisit..
06/28 ONO PHARMACEUTICAL : Opdivo« (nivolumab) Receives Breakthrough Therapy Designati..
06/15 ONO PHARMACEUTICAL : New Data on Opdivo (nivolumab) Indicate Benefit in Heavily ..
More news
Sector news : Generic Pharmaceuticals
11:00pDJALERE : Faces Criminal Probe Over Medicare, Medicaid Billing -- Update
10:56pDJAmgen Profit Rises 13%, 2016 Outlook Raised
10:56pDJAlere Faces Criminal Probe Over Medicare, Medicaid Billing
10:36pDJFacebook Profit, Revenue Jump as Advertisers Flock to Social Network
09:45p Teva purchase of Allergan generics business gets OK with conditions
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( JPY)
Sales 2017 297 336 M
EBIT 2017 -
Net income 2017 77 001 M
Finance 2017 129 348 M
Yield 2017 1,19%
P/E ratio 2017 27,03
P/E ratio 2018 17,36
EV / Sales 2017 7,23x
EV / Sales 2018 5,41x
Capitalization 2 278 581 M
More Financials
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 5 668  JPY
Spread / Average Target 47%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Kazuhito Kawabata Director, Managing Executive Officer & GM-Research
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Kei Sano Director & GM-Corporate Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-11.37%21 592
SUN PHARMACEUTICAL IND..-1.95%28 575
OTSUKA HOLDINGS CO LTD12.23%25 918
BIOMARIN PHARMACEUTICA..-12.16%14 937
ASPEN PHARMACARE HOLDI..25.26%12 238
TAISHO PHARMACEUTICAL ..29.83%9 498
More Results